[ad_1]
Earlier this month, doctors at ADSCC performed the region’s first autologous hematopoietic stem cell transplant (AHSCT) on a multiple sclerosis patient, after which the patient reported an improvement in his overall condition.
The therapy, developed by ADSCC to “reset” a person’s immune system, could be used in patients with relapsing forms of multiple sclerosis, according to a statement from the Abu Dhabi media office.
The transplant’s success follows ADSCC’s pioneering work in providing Covid-19 patients during the pandemic, for which World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus praised the center for its use of cutting-edge Covid-19 treatments. These include UAECell19, launched by ADSCC in 2020, to treat thousands of Covid-19 patients to help restore lung capacity through stem cell therapy.
ADSCC’s Abu Dhabi Bone Marrow Transplantation (AD-BMT) Program was established in 2020 to provide autologous and allogeneic HSCT to adults and children as a comprehensive program and implement different forms of cell therapy such as adoptive cell transfer. ADSCC’s AD-BMT program team worked with the center’s neurology team to treat MS patients under the leadership of AD-BMT program director Dr. Fatima Al Kaabi.
Commenting on the landmark treatment, Dr Al Kaabi said: “At ADSCC we are committed to ensuring that the AD-BMT program meets the highest standards of quality and patient satisfaction throughout all steps of the process including treatment, aftercare and follow-up . With this new therapy, we expand our world-class capabilities, which represent hope and aim to improve the quality of life for everyone.”
Dr Yendry Ventura, CEO of ADSCC, said: “We are very proud of the Abu Dhabi Stem Cell Center’s achievement, becoming the first center in the region to perform BMT on MS patients. We are very proud of the treatment of life. We are grateful for the vision of the UAE’s wise leadership and the support of PureHealth management for making this possible.”
Shaista Asif, Group Chief Operating Officer, PureHealth Group, said: “The timing of a revolutionary bone marrow transplant for an MS patient in the UAE could not have come at a better time as we mark five decades of progress in the UAE’s field.”
ADSCC continues to deliver advanced treatments such as extracorporeal photofractionation therapy in the UAE and is the only center under the PureHealth Group with two open clinical trials. To date, ADSCC under the AD-BMT program has treated 13 cancer patients and one MS patient.
ADSCC is a highly specialized healthcare center focused on cell therapy and regenerative medicine technologies. ADSCC was established in March 2019 to meet the growing domestic and regional demand for highly specialized medical services and treatments. The center is primarily focused on the processing, characterization and storage of cellular products for clinical applications such as regenerative medicine, hematopoietic stem cell transplantation and cell therapy.
[ad_2]
Source link